Latest News

CoreWeave stock fell 25% despite 112% revenue growth, as investors weigh heavy debt against Goldman Sachs' upgrade, rising institutional buying, and scarce permitted data center capacity.

Bank of America issued a double upgrade on CarMax after an FTC pricing rule and strong Q2 FY2027 earnings boosted the used car retailer, though shares have since pulled back from August highs.

The Anthropic CEO's warnings about the dangers posed by AI are raising important questions about the AI lab's growth prospects.

The Vanguard Information Technology ETF has done well in recent years, but it may be overdue for a sharp correction.

A new source of demand might be on the way for the cryptocurrency industry's original meme-token.

The cost of capital is rising, which will be a headwind for Affirm.

Inflation is creeping up, and Fed chair Kevin Warsh appears committed to getting it down to 2%.

Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than the headline suggests.

Nothing is certain in clinical trials, but investors have reason to expect a better outcome in the oral VK2735 trials.

EHang shares show a 160% jump in unusual call options activity, high short interest, and a 19.5-day cover ratio as the company pushes international expansion in Vietnam and Hong Kong.

Instead of focusing on Warren Buffett's stock-picking skills, try to follow his long-term mindset.

Check out the companies making headlines yesterday: Datadog (NASDAQ:DDOG): Cloud monitoring platform Datadog (NASDAQ:DDOG) rose by 4.7% on Monday after easin...

Buying shares of Nike now means missing out on other, potentially more lucrative investing opportunities.

The biggest IPO stock ever is finally climbing again after it plunged earlier this year.

SOXX surged 79.5% over one year but carries higher volatility and fees. XLK offers lower costs, steadier returns, and better income for diversified tech exposure.

Apple stock is fully valued near current levels and needs a new catalyst to move higher, a Wall Street analyst said late Monday.

Arcus Biosciences touted its Merck-rivaling kidney cancer treatment results Tuesday, but shares took a swim.

Bank of America trades at a lower valuation but faces regulatory headwinds, while Goldman Sachs is navigating a strategic pivot.

Past performance doesn't guarantee future results, but it does paint a pretty good picture of what's likely, particularly when the underpinnings of that performance are still in place.

D-Wave Quantum expanded its SkyWater foundry partnership and delivered Italy's first annealing quantum system, as QBTS shares remain down about 58% year to date ahead of earnings.

It's the classic dividend stock, but the yield has come down as the stock soars.

Anthropic and OpenAI are rumored to be approaching IPOs later this year or early next year.

Salesforce stock fell after the enterprise software maker announced the $5.66 billion, all-cash purchase of Braze.

Rapport Therapeutics stock shot higher Tuesday on promising, but mixed, test results for its bipolar treatment.

The key is not to panic.